Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Effects of arsenic compounds on apoptosis, cell cycle
and DNA methylation on myelodysplastic syndromes cells and leukemia cells
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-048-Tuesday
- By: TANAKA, Sachiko (Tokyo University Of Phramacy And Life Sciences, Hachioji, Japan)
- Co-author(s): Sachiko Tanaka: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Fang Su : National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Qing-Bing Zhou: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Hu Xiaomei: National Therapeutic Center of Hematology of Traditional Chinese Medicine, XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Kenji Onda: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Taku Furukawa: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Kentaro Sugiyama: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Anna Kiyomi: Department of Drug Safety Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Hironori Takeuchi: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Sakae Unezaki: Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Haruki Yamada: Department of Kampo Medicines, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Takao Akashi: Department of Pharmaceutics, Tokyo Medical University, Tokyo, Japan
Toshihiko Hirano: Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan - Abstract:
Backgrounds
Arsenic has been used for the treatment of malignant hematologic diseases including Myelodysplastic syndromes (MDS), which are a group of clonal disorders of haematopoietic stem cells characterised by ineffective haematopoiesis and a tendency to evolve into acute myeloid leukaemia (AML). Arsenic trioxide (As2O3) has been confirmed to be .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023